nivolumab

Nivolumab is a fully human monoclonal antibody targeting the programmed death 1 (PD‑1) receptor, functioning as an immune checkpoint inhibitor. By binding to PD‑1 on T cells, it blocks the interaction with its ligands PD-L1 and PD-L2, thereby releasing the inhibition of T-cell activity and enhancing anti-tumor immune responses. Nivolumab is used in the treatment of various cancers including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (bladder cancer), colorectal cancer with microsatellite instability-high or mismatch repair deficiency, hepatocellular carcinoma (HCC), esophageal cancer, gastric/gastroesophageal junction adenocarcinoma, and malignant pleural mesothelioma. It can be administered alone or in combination with other agents such as ipilimumab. Nivolumab was developed by Medarex and Ono Pharmaceutical; Bristol Myers Squibb acquired Medarex in 2009[2][4][5][7].

Brand names

Opdivo欧狄沃保疾伏

Other names

纳武利尤单抗纳武单抗